Medicines For Europe Proposes Revised Remodulation To EU Exclusivity Proposals
Trade Group Believes Market Exclusivity Should Face Incentive Extensions, Not Data Exclusivity
Medicines for Europe proposed several alterations to the European Commission’s planted alterations to market exclusivity incentives at its recent Regulatory and Pharmacovigilance Conference in Brussels, most prominently that various proposed extensions to data exclusivity should instead be used to extend market exclusivity.
You may also be interested in...
New legislation that will come into effect at the beginning of 2025 will change the originator products that UK generics manufacturers must refer to when applying to bring certain products to market.
As EU legislators begin their discussion of the EU pharmaceutical overhaul, EFPIA has issued its formal response to the proposals, with a focus on topics such as unmet medical need, environmental risk assessments and drug shortages.
Pricing and reimbursement processes as well as health technology assessments should be explicitly included in the procedures that can be conducted for generic and biosimilar products without infringing patent rights, according to the European Commission’s legislative revision proposals.